Indicator, Reagent, or Diagnostic Aid

J&J-backed Cellular Origins raises $40M for cell therapy manufacturing

11 hours ago talkbio0Tagged cell therapy manufacturing, Cellular Origins, Constellation platform, cyclic adenosine-5'-trimetaphosphate, Groups, Johnson & Johnson, Manufacturing, Purpura, Thrombotic Thrombocytopenic, robotic automation

Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing

Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data

2 days ago talkbio0Tagged American Epilepsy Society 2025, Antisense Oligonucleotides, Biogen, blockbuster drug, EMPEROR Phase III trial, Epilepsy, Infantile Severe Myoclonic Epilepsy, Jefferies analysts, natural history controls, SCN1A gene, Seizures, Stoke Therapeutics, Zorevunersen

Biogen; Stoke Therapeutics; zorevunersen; Dravet syndrome; epilepsy; antisense oligonucleotide; seizure reduction; blockbuster drug; EMPEROR Phase III trial; American Epilepsy Society 2025; Jefferies analysts; natural history controls; SCN1A

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

3 weeks ago talkbio0Tagged 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene, Cantor, clinical-stage pharmaceutical, Inhibikase Therapeutics, Jefferies, pre-funded, Pricing, public entity

Inhibikase Therapeutics; public offering; common stock; pre-funded warrants; $100 million; Jefferies; BofA Securities; Cantor; clinical-stage pharmaceutical; pricing

Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease

1 month ago talkbio0Tagged Antisense Oligonucleotides, curative potential, Hypertriglyceridemia, Ionis, Pancreatitis, Acute, Phase 3 Clinical Trials, RNA-targeted therapy, Severe (severity modifier), Submission, Triglycerides, TRYNGOLZA, United States Food and Drug Administration

Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer

1 month ago talkbio0Tagged Cancer Therapeutic Procedure, Chief Strategy Officer, Drug Industry, Marcel Reichen, Neoplasms, Precision - temporal, radioligand therapy, Radiopharmaceuticals, Ratio Therapeutics, Strategic Growth

Ratio Therapeutics; Marcel Reichen; Chief Strategy Officer; radiopharmaceuticals; oncology; radioligand therapy; pharmaceutical industry; cancer treatment; strategic growth; precision oncology

Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease

3 months ago talkbio0Tagged access program, Alexander Disease, Antisense Oligonucleotides, Fast Track, Identifier, Improvement, Infrequent, Ionis Pharmaceuticals, nervous system disorder, orphan drug designation, Phase I – III study, Speed, United States Food and Drug Administration, Zilganersen

Ionis Pharmaceuticals; zilganersen; antisense oligonucleotide; Alexander disease; pivotal Phase I–III study; FDA Fast Track designation; rare neurological disease; expanded access program; walk speed improvement; Orphan Drug designation

Genentech’s $700M North Carolina Plant and Telix’s FDA CRL Update

3 months ago talkbio0Tagged biomanufacturing, Complete Response Letter, CRL, genentech, Holly Springs, Manufacturing Facilities, Medicinal product acting as imaging agent (product), metabolic medicines, North Carolina, Obesity, Roche (company), Telix, United States Food and Drug Administration

Genentech; Roche; North Carolina; manufacturing facility; $700 million; Holly Springs; metabolic medicines; obesity treatments; biomanufacturing; Telix; FDA; Complete Response Letter (CRL); imaging agent

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

4 months ago talkbio0Tagged Appointments, biotech leadership, Cancer Therapeutic Procedure, CEO, Commissioner, Hahn, Nucleus RadioPharma, Radiopharmaceuticals, supply chain, United States Food and Drug Administration

Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership

Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

5 months ago talkbio0Tagged Antisense Oligonucleotides, Artificial Intelligence, Automation, Biogen, Biotechnology, expansion, gene therapy, Investments, Manufacturing, North Carolina, Research Triangle Park

Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

5 months ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics